{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:58:56Z","timestamp":1791007136230,"version":"4.1.0"},"reference-count":23,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,4,25]],"date-time":"2013-04-25T00:00:00Z","timestamp":1366848000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite improvements in treatment, the prognosis of relapsed or primary refractory acute lymphocytic leukemia (ALL) remains poor, and outcomes are worse in older adults with the short first complete remission (CR). Attainment of the second CR by salvage therapy would improve the survival of these patients and may enable them to undergo curative treatment with allogeneic hematopoietic stem cell transplantation. The fact that there are diverse salvage protocols for these adult patients but without a striking CR\u2010induction efficacy indicates that efforts are still needed to indentify new effective reinduction regimens. In this study, the CAG regimen (cytarabine, 10\u2009mg\/m<jats:sup>2<\/jats:sup> subcutaneously every 12\u2009h on days 1\u201314; aclarubicin, 5\u20137\u2009mg\/m<jats:sup>2<\/jats:sup> intravenously daily on days 1\u20138; and concurrent granulocyte colony\u2010stimulating factor, 200\u2009\u00b5g\/m<jats:sup>2<\/jats:sup>\/day subcutaneously) was administered to 25 patients with relapsed or refractory ALL, including 11 T\u2010cell ALL (T\u2010ALL) and 14 B\u2010cell (B\u2010ALL) patients (age range, 11\u201361\u2009years; median age, 26\u2009years), to assess its efficacy as a salvage therapy. One course of the CAG regimen resulted in an overall response [CR or partial remission (PR)] rate of 64%, a CR rate of 56% and generally mild adverse effects. An overall response was observed in all 11 T\u2010ALL patients (10 CR and 1 PR) and 35.7% of B\u2010ALL patients (<jats:italic>p<\/jats:italic>\u2009=\u20090.0009). The significant treatment potential of CAG regimen for relapsed or primary refractory ALL, especially for T\u2010ALL patients, described in this report would prepare them for a second CR to pursue longer survival. Copyright \u00a9 2013 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/hon.2051","type":"journal-article","created":{"date-parts":[[2013,4,25]],"date-time":"2013-04-25T09:06:10Z","timestamp":1366880770000},"page":"206-212","source":"Crossref","is-referenced-by-count":16,"title":["Low\u2010dose cytarabine and aclarubicin combined with granulocyte colony\u2010stimulating factor for the treatment of relapsed or primary refractory acute lymphocytic leukemia: a retrospective study of 25 Chinese patients"],"prefix":"10.1002","volume":"31","author":[{"given":"Sheng\u2010Li","family":"Xue","sequence":"first","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital of Soochow University  Suzhou China"},{"name":"Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University  Suzhou China"},{"name":"Key Laboratory of Thrombosis and Hemostasis of Ministry of Health The First Affiliated Hospital of Soochow University  Suzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong\u2010Xia","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of hematology The Second People's Hospital of Huai'an City  Huai'an China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing\u2010Ying","family":"Zou","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Soochow University, School of Nursing of Soochow University  Suzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng\u2010Xing","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital of Soochow University  Suzhou China"},{"name":"Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University  Suzhou China"},{"name":"Key Laboratory of Thrombosis and Hemostasis of Ministry of Health The First Affiliated Hospital of Soochow University  Suzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao\u2010Wen","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital of Soochow University  Suzhou China"},{"name":"Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University  Suzhou China"},{"name":"Key Laboratory of Thrombosis and Hemostasis of Ministry of Health The First Affiliated Hospital of Soochow University  Suzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan\u2010Ming","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of hematology The Second People's Hospital of Huai'an City  Huai'an China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De\u2010Pei","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital of Soochow University  Suzhou China"},{"name":"Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University  Suzhou China"},{"name":"Key Laboratory of Thrombosis and Hemostasis of Ministry of Health The First Affiliated Hospital of Soochow University  Suzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,4,25]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra052603"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.6916"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190903388376"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.014274"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.2950"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19931001)72:7<2155::AID-CNCR2820720715>3.0.CO;2-V"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400861"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1203::AID-CNCR15>3.0.CO;2-3"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21066"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.2.574"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V76.1.163.163"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.6.2214"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404824"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-018192"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.057851"},{"key":"e_1_2_7_18_1","first-page":"10","article-title":"Concurrent use of granulocyte colony\u2010stimulating factor with low\u2010dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study","volume":"9","author":"Yamada K","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1532\/IJH97.A10424"},{"key":"e_1_2_7_20_1","first-page":"165","article-title":"Comparison of low\u2010dose cytosine arabinoside and aclarubicin in combination with granulocyte colony\u2010stimulating factor to intermediate\u2010dose cytosine arabinoside and mitoxantrone with or without etoposide in the treatment of relapsed acute myeloid leukemia","volume":"36","author":"Saito K","year":"1995","journal-title":"Rinsho Ketsueki"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(98)00041-1"},{"key":"e_1_2_7_22_1","first-page":"1279","article-title":"Mechanism of CAG regimen eliminating T\u2010cell acute lymphoblastic leukemia A3 cell line","volume":"16","author":"Wu YL","year":"2008","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"e_1_2_7_23_1","first-page":"61","article-title":"The proliferative effect of G\u2010CSF on acute lymphocytic leukemia cell lines and its synergistic effect with chemotherapy","volume":"32","author":"Xue SL","year":"2011","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.048348"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2051","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2051","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T05:03:09Z","timestamp":1700629389000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,25]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["10.1002\/hon.2051"],"URL":"https:\/\/doi.org\/10.1002\/hon.2051","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,25]]}}}